Combining eltrombopag with antithymocyte globulin and cyclosporine improved complete response rate and overall survival.
The surgeon's recommendation for or against CPM can significantly influence a woman's decision about the surgery.
The benefits far outweigh the risks for most patients, thanks largely to efforts to reduce smoking and to expose less normal tissue to RT.
Sacituzumab govitecan produced durable responses in heavily pretreated patients and had a manageable safety profile.
The use of bisphosphonates as adjuvant therapy can be considered for postmenopausal women with breast cancer who are candidates for systemic therapy.
Consolidation with autologous stem-cell transplantation significantly improved progression-free survival versus triplet induction therapy alone.
Eliminating extracellular chromatin, released by disintegrating blasts, might lower the incidence of hemorrhagic deaths.
A palliative care intervention appeared to benefit patients with lung cancer but not patients with certain gastrointestinal cancers.
Müllerian inhibiting substance is being explored as a reversible protective agent.
Intravenous gamma globulin is recommended at 12 to 20 weeks of gestation for pregnant women with history of neonatal intracranial bleeding.
Prof. Dr. med. Florian Otto
Tumor- und Brustzentrum ZeTuP, St. Gallen
E-Mail: E-Mail anzeigen
Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.
Mortality was similar with active monitoring, prostatectomy, or radiotherapy during 10 years of follow-up.
Pregnant women with inherited thrombophilia have increased risk for VTE, independent of a family history of VTE.
The use of >12 serum tumor marker tests and/or 4 radiographic imaging tests per year provided no survival advantage.
Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.
Andexanet reduced anti–factor Xa activity and restored effective hemostasis in patients with major bleeding.
A 70-gene signature identified patients with high clinical risk and low molecular risk who achieved a 5-year survival rate of 94.7% without chemotherapy.
Declines in light chain levels were achieved in heavily pretreated patients.
The HER2-targeted combination regimen of trastuzumab and lapatinib may have activity in HER2-positive, chemotherapy-refractory disease.
Mutations preventing interferon-receptor signaling and antigen presentation are linked to acquired resistance.
Overall survival was significantly better with S-1 versus gemcitabine.